For the quarter ended September 2025, Haemonetics (HAE) reported revenue of $327.32 million, down 5.3% over the same period last year. EPS came in at $1.27, compared to $1.12 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $311.07 million, representing a surprise of +5.22%. The company delivered an EPS surprise of +13.39%, with the consensus EPS estimate being $1.12.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Haemonetics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net revenues- United States: $240.09 million versus $220.36 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -6.2% change.
- Net revenues- Europe: $42.97 million versus $44.25 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +2.3% change.
- Net revenues- Japan: $18.01 million compared to the $17.55 million average estimate based on two analysts. The reported number represents a change of +9.7% year over year.
- Net revenues- Plasma: $125.36 million compared to the $113.89 million average estimate based on three analysts. The reported number represents a change of -9.5% year over year.
- Net revenues- Hospital: $145.5 million versus the three-analyst average estimate of $147.99 million. The reported number represents a year-over-year change of +5.1%.
- Net revenues- Blood Center: $56.45 million compared to the $49.04 million average estimate based on three analysts. The reported number represents a change of -17.6% year over year.
- Operating income- Plasma: $42.59 million versus $60.95 million estimated by two analysts on average.
- Operating income- Hospital: $29.86 million compared to the $10.86 million average estimate based on two analysts.
- Operating income- Blood Center: $14.83 million versus $15.51 million estimated by two analysts on average.
View all Key Company Metrics for Haemonetics here>>>
Shares of Haemonetics have returned -0.5% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Haemonetics Corporation (HAE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
